Arpeggio Bio, a preclinical company whose technology provides a mechanistic understanding of how drugs work, today announced that it has closed a $3.2 million seed financing round, which was oversubscribed by over $2 million. Funding will support the ongoing development of a nascent RNA drug screen. “We’re excited to have...